Arthroscopy Procedure and Products Market | Latest Analysis, Demand Trends, Growth Forecast

Market Summary and Growth Forecast

The global Arthroscopy Procedure and Products Market is valued at $21,850 million in 2026 and is expected to appreciate to $38,420 million by 2035, at a CAGR of 6.5%.

The Arthroscopy Procedure and Products Market covers minimally invasive joint procedures and the products used to perform them. These include arthroscopes, camera systems, light sources, fluid-management systems, shavers, radiofrequency devices, implants, fixation products and procedure-specific disposables.

The estimate also includes direct revenue generated from arthroscopic procedures performed by hospitals, ambulatory surgery centers and orthopedic facilities. Rehabilitation, diagnostic imaging outside the procedure, pharmaceutical treatment and open surgical procedures are excluded.

Global Market Forecast

Figures represent analyst estimates based on procedure volumes, treatment economics, product utilization and regional adoption patterns.

Business Relevance During 2026–2035

Arthroscopy sits between conservative treatment and open orthopedic surgery. It gives surgeons access to a joint through small incisions, often reducing tissue damage, hospital stays and recovery periods.

Its commercial importance is expanding because orthopedic care is moving toward less invasive intervention. Hospitals also want procedures that support shorter operating-room cycles and earlier discharge. So, arthroscopy fits both clinical and financial priorities.

Demand will be supported by sports-related injuries, ligament damage, cartilage disorders, rotator-cuff tears and age-related joint conditions. A larger physically active population is another factor. Many patients in their forties, fifties and sixties are seeking treatment that allows them to return to work or recreational activity without undergoing full joint replacement.

That said, volume growth will not be uniform across every procedure. Routine arthroscopic intervention for degenerative knee conditions faces tighter clinical scrutiny in several healthcare systems. Growth will instead come from procedures with stronger evidence, including ligament reconstruction, meniscal repair, shoulder stabilization, rotator-cuff repair, hip preservation and cartilage restoration.

Technology as a Growth Force

Visualization quality is becoming a major purchasing criterion. Hospitals are replacing conventional high-definition towers with 4K, chip-on-tip and digitally integrated systems. Better image quality helps surgeons identify small tears, cartilage defects and tissue boundaries.

Needle arthroscopy is also widening the range of settings in which minimally invasive joint evaluation can be performed. Smaller-diameter scopes may support selected office-based procedures and reduce dependence on conventional operating-room infrastructure.

Product demand is also moving toward knotless anchors, all-suture anchors, adjustable-loop fixation systems and more procedure-specific instruments. These products can simplify surgical steps and reduce implant bulk.

Single-use components are receiving greater attention where infection control, equipment availability and reprocessing costs are significant concerns. However, disposable systems must demonstrate clear economic value. A hospital will not shift from reusable equipment solely because a product is easier to handle.

Regulation and Reimbursement

Arthroscopy products must meet strict requirements for biocompatibility, sterility, mechanical performance, electrical safety and clinical reliability. Implantable anchors and fixation systems receive particularly close review because failure may require revision surgery.

Regulatory requirements under the US Food and Drug Administration, the European medical-device framework and other national authorities may increase development costs. Manufacturers must also manage post-market surveillance, traceability and sterilization validation.

Reimbursement will influence procedure location. Payers are encouraging suitable cases to move from inpatient hospitals to outpatient departments and ambulatory surgery centers. This may lower the average cost per procedure while increasing total procedure access.

The commercial result is mixed. Providers face price pressure, but device suppliers gain access to a wider customer base. Products designed for fast setup, compact storage and standardized workflows are likely to perform well in outpatient settings.

Production and Supply-Chain Factors

The production ecosystem depends on medical-grade polymers, stainless steel, titanium, optical components, image sensors, sterile packaging and precision-machined instruments. A shortage in any one category can delay product availability.

Implant suppliers must maintain tight control over mechanical strength and surface quality. Visualization-system manufacturers depend on specialized electronic components and sensors. Disposable products require reliable sterilization and packaging capacity.

During the forecast period, larger manufacturers are expected to increase dual sourcing and regional assembly. They may also standardize components across product families. This can lower inventory requirements and reduce exposure to individual supplier disruptions.

Key Consumers and Clients

The main purchasing and user groups include:

• Multispecialty hospitals, which perform complex and high-acuity procedures.
• Ambulatory surgery centers, which focus on efficient outpatient intervention.
• Orthopedic and sports-medicine hospitals, where arthroscopy represents a core service line.
• Orthopedic surgeons and sports-medicine specialists, who influence product selection.
• Group purchasing organizations, which negotiate prices across hospital networks.
• Public healthcare systems, which assess both clinical benefit and procedural cost.
• Private insurers and managed-care organizations, which influence reimbursement and procedure location.
• Medical-device distributors, particularly in markets where manufacturers lack direct sales infrastructure.

For investors and suppliers, the Arthroscopy Procedure and Products Market remains attractive because it combines recurring disposable revenue with higher-value capital equipment and implants. The strongest companies are likely to be those that can connect visualization, instruments, implants and workflow support rather than selling isolated products.

Market Segmentation and Forecast Scope

The Arthroscopy Procedure and Products Market can be assessed by revenue component, product type, procedure area, end user and region. Each dimension reflects a different buying decision. Hospitals purchase capital equipment differently from implants, while surgeons select products according to anatomy, repair technique and clinical preference.

By Revenue Component

Procedure-Related Services

This segment includes the direct economic value of arthroscopic procedures. It covers surgeon services, facility utilization, anesthesia and operating-room support, while excluding separately counted product revenue.

Procedure-related services account for an estimated 61.5% of the market in 2026. The segment remains the largest because every intervention generates clinical-service revenue, regardless of the implant or equipment brand used.

Growth will follow procedure volumes, reimbursement levels and the shift toward outpatient care. Revenue per case may decline in some markets as procedures move to lower-cost facilities. Even so, higher case volumes should offset part of this pressure.

Arthroscopy Products

This segment covers reusable equipment, implants, powered instruments and disposable accessories. Product revenue is more concentrated than service revenue, with a limited number of multinational companies controlling major technology platforms.

Products are likely to grow slightly faster than procedure services. Premium implants, digital visualization and single-use components are increasing the product value attached to selected cases.

By Product Type

Arthroscopes and Visualization Systems

This category includes rigid and flexible arthroscopes, cameras, monitors, light sources and image-processing units.

Capital replacement cycles are relatively long, but the transition toward 4K, integrated imaging and smaller scopes is creating upgrade demand. Vendors increasingly sell visualization systems as part of a connected operating-room platform.

Implants and Fixation Devices

This segment includes suture anchors, interference screws, cortical buttons, fixation loops, meniscal repair systems and related implants.

It is one of the most commercially important product groups because implants generate recurring revenue for every procedure. Knotless fixation, all-suture anchors and low-profile designs are likely to gain wider adoption.

Powered Shaver Systems

Powered systems are used to cut, resect or remove damaged tissue. The installed console creates demand for blades, burrs and other compatible disposables.

The segment benefits from recurring consumable sales. However, competition is intense, and hospitals often negotiate bundled contracts covering consoles and disposables.

Radiofrequency and Ablation Systems

These systems support tissue removal, contouring and bleeding control. Adoption is increasing where surgeons require precise tissue management.

Future development will focus on controlled energy delivery and reduced thermal damage. Safety remains important because excessive heat can affect surrounding cartilage and tissue.

Fluid-Management Systems

Pumps, tubing and pressure-control systems maintain joint-space visibility during surgery.

Automated pressure adjustment and improved fluid monitoring are making these systems more efficient. Disposable tubing and procedure kits provide a recurring revenue stream.

Hand Instruments and Procedure Disposables

This group includes cannulas, graspers, punches, sutures, guidewires, probes and access devices.

It is a mature segment, but procedure-specific kits may support growth. Standardized kits can reduce preparation time and simplify inventory management in ambulatory surgery centers.

By Procedure Area

Knee Arthroscopy

Knee procedures represent an estimated 42.8% of total market revenue in 2026. The segment includes anterior cruciate ligament reconstruction, meniscal repair, cartilage procedures and selected diagnostic interventions.

Knee arthroscopy remains the largest procedure category because ligament and meniscal injuries are common across professional sports, recreational activity and the general population.

However, growth will be moderate. Payers and clinical bodies have become more selective regarding arthroscopy for degenerative knee disease. Suppliers will therefore focus more heavily on tissue preservation, repair and reconstruction rather than simple debridement.

Shoulder Arthroscopy

Shoulder arthroscopy includes rotator-cuff repair, instability treatment, labral repair, decompression and related procedures.

This is one of the most strategic categories. Demand is supported by sports injuries, repetitive occupational strain and age-related tendon damage. Shoulder procedures also use a relatively high number of anchors and fixation products, which raises product revenue per case.

Hip Arthroscopy

Hip arthroscopy is projected to be one of the fastest-growing procedure areas through 2035.

Growth is being supported by improved diagnosis of femoroacetabular impingement, labral damage and cartilage abnormalities. The procedure remains technically demanding, so expansion depends on specialist training and appropriate patient selection.

Ankle and Foot Arthroscopy

This segment includes treatment of cartilage lesions, impingement, instability and sports injuries.

It has a smaller procedure base but is gaining attention as surgeons adopt less invasive techniques for anatomically difficult joints.

Elbow and Wrist Arthroscopy

These procedures are used for selected ligament injuries, loose bodies, cartilage damage and joint disorders.

Demand is concentrated among specialist surgeons. Growth will remain steady rather than rapid because procedure volumes are comparatively limited.

Other Joint Procedures

This category includes smaller-joint applications and emerging minimally invasive techniques that do not fit the major anatomical groups.

By End User

Hospitals

Hospitals remain the main setting for complex arthroscopy, revision procedures and cases involving patients with additional medical risks.

They also account for most capital-equipment purchases. Large hospital groups frequently negotiate integrated contracts covering cameras, towers, instruments, implants and maintenance.

Ambulatory Surgery Centers

Ambulatory surgery centers are expected to be the fastest-growing end-user segment.

They offer lower facility costs and shorter patient stays. Their procurement priorities differ from those of large hospitals. They prefer compact equipment, predictable disposable costs and products that reduce operating-room turnover time.

Use case: An outpatient center performing repeated shoulder and knee procedures may select one integrated visualization platform and standardize implants across a small number of surgeons. This reduces training requirements and inventory complexity.

Orthopedic and Sports-Medicine Clinics

Specialty clinics participate in diagnosis, minor intervention, post-operative management and selected office-based arthroscopy.

Needle arthroscopy may expand the role of these facilities, especially for direct joint visualization where conventional imaging does not provide a clear diagnosis.

By Region

North America

North America is the leading regional market. Its position reflects high procedure utilization, established sports-medicine infrastructure, widespread insurance coverage and strong adoption of premium implants.

The United States also has a large ambulatory surgery network. This supports faster adoption of equipment designed for outpatient procedures.

Europe

Europe represents a mature but stable market. Germany, France, the United Kingdom, Italy and Spain account for a substantial portion of regional demand.

Growth is moderated by public-sector budget controls and centralized procurement. However, demand for joint-preserving procedures, sports-medicine care and efficient outpatient treatment remains positive.

Asia Pacific

Asia Pacific is expected to record the fastest regional growth through 2035.

China, India, Japan, South Korea and Australia are the main markets. Expansion will be supported by improving hospital infrastructure, surgeon training and growing private healthcare expenditure.

Price sensitivity remains important. Mid-range equipment, reusable systems and locally produced instruments will continue to compete with premium multinational brands.

Latin America, Middle East and Africa

The LAMEA region offers selective growth opportunities rather than uniform expansion.

Brazil, Mexico, Saudi Arabia, the United Arab Emirates and South Africa have the strongest specialist-care infrastructure. Demand elsewhere may be constrained by limited reimbursement, imported-product costs and shortages of trained surgeons.

Strategic Segment Outlook

The most attractive opportunities are likely to include:

• Hip-preservation procedures.
• Shoulder repair and stabilization.
• Ambulatory surgery center equipment.
• Knotless and all-suture fixation.
• Needle arthroscopy.
• Integrated visualization and documentation platforms.
• Procedure-specific disposable kits.

The market will gradually move away from general-purpose hardware. Suppliers will compete through complete procedural ecosystems, surgeon training and facility-level efficiency.

Market Trends and Business Innovations

Innovation in the Arthroscopy Procedure and Products Market is moving beyond better cameras and smaller instruments. Product development now focuses on tissue preservation, workflow efficiency, data integration and treatment consistency.

Shift Toward Joint Preservation

Patients and surgeons are seeking treatment options that delay or avoid joint replacement. This is increasing investment in meniscal repair, ligament reconstruction, cartilage restoration and biologically supported tendon repair.

Historically, some arthroscopic procedures removed damaged tissue. Newer techniques aim to preserve and repair it. This creates demand for more advanced suturing systems, scaffolds, anchors and fixation devices.

Expert view: Tissue-preserving procedures could increase the product value per case because repair generally requires more specialized implants than basic resection.

Knotless and Low-Profile Fixation

Knotless anchors are becoming more common in shoulder, hip and selected knee procedures. They simplify suture management and may reduce the amount of material placed around the repair site.

All-suture anchors are also receiving attention. They require smaller bone tunnels than traditional metal or polymer anchors. This may be useful in revision procedures or areas with limited bone volume.

Manufacturers are developing broader anchor families rather than isolated products. A single platform may include different sizes, materials and insertion systems for multiple joints.

Improved Visualization

The transition from conventional high-definition imaging to 4K visualization is continuing. Better image resolution may improve tissue identification and surgical precision, particularly in small or crowded joint spaces.

Chip-on-tip technology places the imaging sensor closer to the surgical field. This can reduce dependence on conventional optical pathways and support smaller device designs.

Some platforms also integrate fluorescence, digital zoom, image enhancement and automatic light adjustment. These functions are intended to improve visualization without repeatedly interrupting the procedure.

Stryker continues to position its 1788 visualization platform around advanced imaging and operating-room integration. Arthrex has expanded its minimally invasive visualization ecosystem through products such as the NanoScope. Smith+Nephew and CONMED are also investing in connected visualization and sports-medicine workflows.

Needle Arthroscopy and Office-Based Evaluation

Needle arthroscopes use a smaller diameter than conventional systems. Their role is developing in joint evaluation and selected minor procedures.

The technology may allow direct visualization in outpatient clinics or procedure rooms. It can complement magnetic resonance imaging when findings remain unclear.

Cost remains an important question. Office-based arthroscopy must provide enough diagnostic or procedural value to justify equipment, training and sterile-supply expenses.

Use case: A sports-medicine physician may use needle arthroscopy to directly assess a suspected cartilage or meniscal abnormality before deciding whether a full operating-room procedure is required.

Single-Use Arthroscopy Systems

Single-use arthroscopes can remove reprocessing requirements and reduce concerns about equipment availability. They may also help smaller facilities that cannot support a full reusable-camera infrastructure.

Adoption will depend on total procedure economics. Disposable systems reduce cleaning and maintenance costs but increase waste and per-case product spending.

Hospitals will assess the complete cost rather than the purchase price alone. This includes reprocessing labor, repair expense, downtime, infection risk and storage requirements.

Environmental concerns may slow adoption in healthcare systems with strict waste-reduction targets. Suppliers will face pressure to improve material recovery and packaging efficiency.

Biologic and Scaffold-Assisted Repair

Biologic augmentation is becoming more closely connected with arthroscopic repair. Collagen scaffolds, platelet-based treatments and tissue-regeneration products are being evaluated for tendon and cartilage applications.

The strongest commercial opportunities will come from products supported by measurable clinical outcomes. Surgeons and payers will require evidence of better healing, lower re-tear rates or delayed joint replacement.

Smith+Nephew has expanded its joint-preservation position through technologies such as the REGENETEN bioinductive implant and its acquisition of CartiHeal. The latter added the Agili-C cartilage-repair platform to its portfolio.

CONMED strengthened its sports-medicine offering through the acquisition of Biorez, developer of the BioBrace implant. The transaction reflects broader industry interest in products that combine mechanical reinforcement with biologic healing support.

Stryker expanded its soft-tissue repair capabilities through its acquisition of Artelon, adding synthetic tissue-reinforcement technology to its orthopedic portfolio.

These transactions show where strategic capital is moving. Large device companies are not only buying conventional implants. They are building platforms around repair quality, tissue regeneration and joint preservation.

Smarter Fluid and Energy Management

Fluid-management systems are becoming more automated. Newer pumps can adjust pressure and flow according to procedural conditions.

Better control may improve visibility while limiting unnecessary fluid use and tissue swelling. Integrated monitoring can also alert staff when pressure or fluid conditions move outside a preferred range.

Radiofrequency systems are being designed to provide more controlled tissue ablation. Developers are focusing on energy precision and thermal safety.

The next stage will involve closer communication between pumps, shavers, energy systems and visualization equipment. This could allow the operating room to function as one coordinated platform.

Selective Use of Artificial Intelligence

Artificial intelligence has a developing but still limited role in arthroscopy. Current applications are more realistic in image management, procedure documentation and workflow support than in autonomous surgical decision-making.

Potential uses include:

• Identifying anatomical structures in recorded video.
• Flagging possible tissue abnormalities.
• Organizing procedure footage.
• Automating parts of surgical documentation.
• Measuring procedure time and equipment utilization.
• Supporting surgeon training through video review.

Clinical deployment will require large, well-labelled video datasets. Algorithms must also perform reliably across different camera systems, surgeons and patient anatomies.

Expert view: AI is unlikely to replace arthroscopic judgement during the forecast period. Its nearer-term value will come from documentation, training and operating-room analytics.

Growth of Ambulatory Surgery

Procedure migration toward ambulatory surgery centers is changing product development. Equipment must be easier to install, operate and maintain.

Suppliers are responding with compact towers, simplified interfaces, procedure kits and service contracts. Some are offering equipment through leasing or usage-linked models rather than requiring a large upfront purchase.

This may widen market access for smaller facilities. It also creates a more recurring revenue structure for manufacturers.

Expert view: The winning outpatient platform may not be the system with the highest technical specification. It may be the one that offers the lowest cost per completed procedure.

Digital Integration and Procedure Data

Hospitals increasingly want arthroscopy systems to connect with electronic records, image archives and operating-room management software.

Automatic capture of images, videos and device settings can reduce manual documentation. It can also support quality review and surgeon training.

Device companies may use aggregated operational data to improve maintenance and inventory planning. However, cybersecurity and patient-data governance will become more important as equipment becomes connected.

Partnerships and Commercial Models

Partnership activity is likely to expand across device companies, surgeon-training organizations, ambulatory surgery groups and digital-health providers.

Surgeon education remains commercially important because arthroscopy outcomes depend heavily on technique. Manufacturers often support laboratory training, cadaver workshops and procedure-specific certification.

Hospitals are also asking for broader contracts. Instead of purchasing individual cameras, pumps and implants separately, they may select a strategic supplier for an entire sports-medicine service line.

This encourages companies to build complete ecosystems. Arthrex, Stryker, Smith+Nephew, CONMED, Johnson & Johnson MedTech and Zimmer Biomet are therefore competing across multiple parts of the procedure rather than within one narrow product category.

Outlook for Innovation

By 2035, innovation will be measured less by individual device features and more by the complete treatment pathway. Successful platforms will combine high-quality visualization, efficient instruments, tissue-preserving implants and digital documentation.

The Arthroscopy Procedure and Products Market will remain surgeon-influenced, but purchasing decisions will involve more stakeholders. Clinical outcomes, procedure time, facility economics and supply reliability will all affect product selection.

Expert view: Future market leadership will depend on whether a company can improve both the repair and the economics of delivering that repair.

Competitive Intelligence and Benchmarking

Competition in the Arthroscopy Procedure and Products Market is conctrong portfolio now requires more than implants. Hospitals increasingly assess visualization, fluid management, tissue resection, fixation, disposables, service support and surgeon education together.

Competitive Benchmarking Matrix

Analyst score: 5 = very strong, 1 = limited presence.

Arthrex

Arthrex has one of the broadest portfolios dedicated specifically to arthroscopy and sports medicine. Its coverage extends across visualization, fluid management, powered instruments, sutures, fixation devices, biologic products and small-incision procedures.

Its market strength comes from procedural depth. The company develops complete solutions for shoulder, knee, hip, foot, ankle, hand and wrist procedures rather than competing through a limited group of devices.

Surgeon education is another important advantage. Training laboratories, clinical videos and procedure-focused learning support product adoption and surgeon loyalty. The company states that it develops more than 1,000 products and related procedures annually, although not all are arthroscopy products. position is particularly strong in soft-tissue fixation, ligament reconstruction, minimally invasive visualization and surgeon-developed procedural systems. However, its privately held structure provides less public financial visibility than listed competitors.

Stryker

Stryker competes through an integrated sports-medicine platform covering visualization, arthroscopic resection, fluid management, biologic products, implants and instruments for shoulder, knee, hip and small-joint procedures. fits from established hospital relationships across operating-room equipment and orthopedics. This creates opportunities to bundle arthroscopy systems with broader capital-equipment and service contracts.

Its strongest commercial advantage is workflow integration. A hospital or ambulatory surgery center can source cameras, scopes, pumps, resection equipment, fixation products and data-management support from one vendor.

The portfolio is well placed for large hospital networks and outpatient surgery groups seeking procurement standardization. That said, the company faces strong surgeon-level competition from more specialized sports-medicine suppliers.

Smith+Nephew

Smith+Nephew holds a strong position in joint repair, sports medicine and tissue-preservation technologies. Its portfolio spans fixation implants, meniscal repair, cartilage treatment, radiofrequency systems, mechanical resection, fluid management and biologically supported tendon repair. rategic strength lies in advanced healing. It has invested in products intended to reinforce rotator-cuff repairs, support cartilage restoration and improve biological healing alongside mechanical fixation.

This provides differentiation from companies that compete mainly through conventional anchors or instrumentation. It may also increase revenue per procedure because biologic augmentation is added to the standard repair workflow.

Its 2026 relationship with KARL STORZ strengthens access to advanced visualization and operating-room integration without requiring Smith+Nephew to develop every capital-equipment component internally. CONMED is a focused orthopedic and surgical-technology competitor. Its arthroscopy portfolio includes visualization, powered resection, fluid management, radiofrequency devices, instruments, fixation implants and reinforced biologic scaffolds. etes effectively in both capital equipment and recurring disposables. This gives it a balanced revenue structure. Its installed equipment supports demand for blades, tubing, probes and other procedure-specific products.

Its reinforced healing platform is becoming an important differentiator in shoulder, knee and ligament repair. The company is developing delivery systems that make biologic augmentation easier to incorporate into an arthroscopic procedure. maller than the largest orthopedic groups. So, disciplined product launches and targeted surgeon conversion are important to its market-share strategy.

Johnson & Johnson MedTech

Johnson & Johnson MedTech, through DePuy Synthes, offers arthroscopic equipment and soft-tissue repair products for shoulder, knee, hip and small-joint procedures.

Its portfolio includes visualization, fluid management, tissue resection, sutures, anchors, cortical fixation and meniscal-repair technologies. fits from a large global commercial organization and long-standing hospital relationships. These capabilities are particularly useful in centralized procurement environments and large healthcare systems.

However, arthroscopy represents one part of a much broader orthopedic business. The company may therefore have less specialized visibility than pure sports-medicine competitors in some surgeon communities.

Its opportunity lies in linking arthroscopic repair with trauma, reconstruction and broader orthopedic care pathways.

Zimmer Biomet

Zimmer Biomet combines soft-tissue repair implants with integrated arthroscopy equipment. Its offering covers ligament reconstruction, shoulder repair, suture anchors, resection, fluid management and advanced visualization. expanded its capital-equipment proposition through compact platforms that combine several surgical functions within fewer consoles. It also offers reusable and sterile single-use visualization options within the same equipment ecosystem. is relevant for ambulatory surgery centers that want to reduce equipment footprint and setup complexity.

Its main challenge is brand perception. Zimmer Biomet is more strongly associated with joint reconstruction than arthroscopy. Continued investment in sports medicine will be required to increase specialist mindshare.

KARL STORZ

KARL STORZ is a major specialist in endoscopy, visualization and reusable surgical instrumentation. Its arthroscopy portfolio covers scopes, cameras, instruments and modular systems for procedures from the shoulder to the ankle. advantage is image quality and operating-room integration. The company also has strong positions across multiple surgical specialties, allowing hospitals to use related visualization infrastructure across departments.

Its direct exposure to implants and biologic products is lower than that of orthopedic device companies. So, partnerships are strategically important.

The collaboration with Smith+Nephew combines KARL STORZ visualization and integration technologies with an established portfolio of sports-medicine implants, tissue-repair devices, resection systems and fluid-management products. mpetitive Outlook**

The competitive market can be divided into three groups:

• Integrated arthroscopy leaders: Arthrex, Stryker and Smith+Nephew.
• Focused challengers and diversified orthopedic suppliers: CONMED, Johnson & Johnson MedTech and Zimmer Biomet.
• Visualization and instrumentation specialists: KARL STORZ and other endoscopy-focused suppliers.

Future market share will depend on four factors: surgeon preference, clinical evidence, outpatient workflow efficiency and the ability to offer commercially attractive bundles.

Expert view: Individual implant performance will remain important, but procurement decisions will increasingly be won at the platform level.

Regional Landscape and Adoption Outlook

Regional demand varies according to procedure volumes, reimbursement, surgeon availability, hospital infrastructure and the price of imported implants.

The following estimates remain consistent with the global 2026 value of $21,850 million.

Regional Revenue and Growth Benchmark

Figures are analyst estimates covering arthroscopy products and direct procedure-related revenues.

United States

The United States is the largest national market. It has a high concentration of orthopedic surgeons, sports-medicine practices, ambulatory surgery centers and hospital-based orthopedic programs.

Knee and shoulder procedures generate the largest revenue base. Hip preservation, cartilage repair and biologically supported rotator-cuff repair offer stronger growth potential.

The continued migration of suitable procedures into ambulatory surgery centers is changing purchasing criteria. Compact equipment, predictable disposable costs and short room-turnover times are increasingly important.

For 2026, the Centers for Medicare & Medicaid Services finalized a 2.6% update to ASC payment rates for facilities meeting relevant quality-reporting requirements. The change supports outpatient facility economics, although reimbursement varies by procedure and payer. is demanding but transparent. Products may require premarket notification, premarket approval or other controls according to device classification and risk.

Private insurance and employer-sponsored healthcare support premium product adoption. At the same time, payer scrutiny limits low-value procedures, particularly arthroscopy used for poorly selected degenerative conditions.

Europe

Europe is led by Germany, the United Kingdom, France, Italy and Spain. Germany has a large orthopedic-device base and extensive specialist infrastructure. The United Kingdom has strong clinical expertise but tighter public-sector funding controls.

Most Western European markets have established arthroscopy practices. Growth is therefore driven more by replacement equipment, advanced repair products and outpatient migration than by first-time adoption.

The European Medical Device Regulation raises requirements for clinical evidence, traceability, post-market surveillance and notified-body assessment. Extended transition arrangements reduce immediate supply disruption but do not remove the cost of MDR compliance. 026**, four EUDAMED modules became mandatory, including actor registration, device registration, notified-body certificates and market surveillance. This increases transparency but also adds data-management responsibilities for manufacturers. healthcare systems place strong pressure on implant prices. So, suppliers must demonstrate reduced revision risk, shorter procedure time or better resource utilization.

Central and Eastern Europe offer higher procedure growth from a smaller base. However, lower hospital budgets favour reusable instruments and mid-priced implants.

China

China is moving from imported premium systems toward a mixed market involving multinational and domestic suppliers.

Large hospitals in Beijing, Shanghai, Guangzhou, Shenzhen and other major cities have well-developed orthopedic departments. Adoption outside leading urban centers remains less consistent.

The country’s centralized procurement of sports-medicine consumables covers products such as suture anchors, knotless anchors, fixation devices, repair sutures and soft-tissue reconstruction materials. Beijing began implementing the selected results in June 2024 under a two-year procurement cycle. nds access but places substantial pressure on selling prices. Multinational suppliers may need to adjust product configuration, local production and distribution costs to protect margins.

Domestic companies are likely to gain share in standard fixation and instrument categories. Premium international suppliers will remain stronger where clinical differentiation, surgeon preference or advanced visualization is important.

Procedure volumes should continue to rise with hospital investment, sports participation and greater availability of trained surgeons. Revenue growth will be slower than volume growth where procurement reduces average prices.

India

India is expected to record the fastest growth among the major markets assessed.

Current demand is concentrated in private hospitals and orthopedic centers in cities such as Mumbai, Delhi, Bengaluru, Chennai, Hyderabad and Pune. Secondary cities represent the next layer of expansion.

All medical devices in India fall under the Drugs and Cosmetics Act and the Medical Devices Rules, 2017. Importers and domestic manufacturers must meet licensing requirements according to device class. s use international visualization systems and implants. However, price sensitivity is high outside major private networks.

Domestic suppliers are stronger in instruments, basic consumables and lower-cost implants. Multinational companies retain an advantage in advanced fixation systems, cameras and surgeon-training support.

Insurance penetration is increasing, but a large share of elective orthopedic care still depends on private payment. This limits adoption of expensive biologic augmentation and premium disposable systems.

The largest opportunity lies in mid-priced equipment and implants that offer reliable performance without the cost structure of top-tier imported platforms.

Japan

Japan is a mature market with advanced hospital infrastructure, experienced surgeons and strict quality expectations.

The market benefits from an ageing population and high standards of orthopedic care. However, overall growth is moderated by demographic pressure on healthcare budgets and controlled reimbursement.

Medical devices are regulated by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. The PMDA conducts scientific reviews, while the MHLW retains responsibility for administrative approval and reimbursement policy. proven clinical performance and long-term supplier reliability. Product conversion can therefore be slower than in markets driven mainly by purchasing price.

Small-joint procedures, shoulder repair and tissue-preserving techniques offer opportunities. Domestic distribution and surgeon education remain essential for international suppliers.

South Korea

South Korea has a technically advanced hospital system and relatively rapid adoption of high-resolution imaging and minimally invasive surgery.

Demand is concentrated in Seoul and other major urban areas. Private hospitals actively compete through specialist orthopedic services and newer technology.

Medical devices are classified and reviewed through the Ministry of Food and Drug Safety. Lower-risk devices may follow certification routes, while higher-risk and novel devices require MFDS approval and technical documentation. o strengthened public reporting on medical-device approvals, improving visibility into approval and certification trends. rs opportunities for compact visualization, advanced anchors and digital procedure management. Local suppliers create price competition in instruments and standard consumables.

Middle East

The Middle East is relevant where government healthcare investment, private hospital construction and medical tourism support advanced orthopedic services.

Saudi Arabia and the United Arab Emirates are the main commercial markets. Qatar and Kuwait provide smaller but higher-value opportunities.

Saudi Arabia’s Health Sector Transformation Program aims to improve healthcare access, efficiency, service quality and value-based delivery. This supports investment in modern hospital infrastructure and specialist surgical services. uppliers must meet national authorization and establishment-licensing requirements. In Saudi Arabia, the SFDA maintains device listings and regulates marketing authorization, importation and local representation. d hospitals remain major buyers. Private hospital groups and sports-medicine centers are also expanding.

The region depends heavily on imported technology. This creates opportunities for international suppliers but exposes buyers to currency, logistics and distributor-margin pressures.

Funding and Procurement Comparison

Expert view: India may provide the fastest percentage growth, while the United States will continue to generate the largest absolute revenue addition.

Recent Developments, Opportunities and Restraints

Recent Developments

• April 2025 – CONMED received expanded US FDA clearance for a reinforced biologic scaffold used in additional extra-articular ligament-repair applications. The clearance widened the addressable range of soft-tissue procedures and strengthened the commercial case for biologically supported repair. Arthrex launched a new powered orthopedic instrument platform.** The system was designed for use across sports medicine, trauma, joint reconstruction and extremity procedures, supporting consolidation of powered equipment across operating rooms. – CONMED launched an arthroscopic delivery system for reinforced rotator-cuff augmentation.** The platform was developed to simplify placement of a biologic scaffold during shoulder repair and reduce procedural complexity. 5 – CMS finalized a 2.6% update to US ambulatory surgery center payment rates for 2026.** The change applies to facilities meeting relevant quality-reporting requirements and provides moderate support for outpatient procedure economics. 6 – KARL STORZ and Smith+Nephew announced a strategic US relationship.** The collaboration combines visualization and operating-room integration with sports-medicine implants, cartilage repair, biologic products, resection and fluid-management technologies. ies and Business Insights**

Emerging-Market Expansion

India, China, Southeast Asia and selected Middle Eastern markets have lower arthroscopy penetration than North America and Western Europe.

Mid-priced imaging systems, reusable instruments and locally manufactured fixation products can increase access. Suppliers that adapt pricing and service models to local hospital budgets may gain faster adoption.

ASC-Focused Product Platforms

Ambulatory surgery centers need compact equipment, quick setup and predictable per-case costs.

Integrated consoles, procedure-specific kits and equipment-leasing models can reduce initial capital requirements. This may help smaller facilities add arthroscopy services without building a full hospital-scale operating room.

Biologically Supported Repair

Scaffolds, cartilage-repair products and tissue-preservation technologies can raise product revenue per procedure.

The opportunity depends on clinical proof. Products showing lower re-tear rates, better tissue healing or fewer revision procedures will have a stronger reimbursement and procurement case.

Market Restraints

Procedure Appropriateness

Arthroscopy is not equally effective for every degenerative joint condition. Tighter clinical guidelines and payer review may limit procedures with weak evidence.

Pricing Pressure

Centralized procurement, hospital consolidation and group purchasing reduce implant and disposable prices. Smaller suppliers may struggle to maintain margins while funding clinical studies and surgeon education.

Training and Infrastructure Gaps

Advanced hip, shoulder and cartilage procedures require specialist skills. Markets with limited surgeon training, imaging capacity or rehabilitation infrastructure will adopt these techniques more slowly.